NDMA advocates label reform through expansion of FDA's flexibility policy.
This article was originally published in The Tan Sheet
NDMA URGING LABEL REFORM THROUGH "FLEXIBILITY POLICY" EXPANSION, Senior VP-Science and Technology William Soller, PhD, declared at a Sept. 29 FDA public hearing on OTC labeling. The policy, adopted by FDA in 1986, allows the use of alternate, non-monograph wording in the Indications and Directions sections of OTC labels so long as the statements are truthful and not misleading. The policy states that "within limits, there can be various ways of accurately stating the same thing, some of which may even be more meaningful" than the monograph language.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC